Anna Mc Laughlin, Dr. rer.nat., MBA

Senior Director, MIDD Consultant

Portrait-of-Anna-Mc-Laughlin_Pharmetheus

Bio

  • Joined Pharmetheus in 2022, actively working in client projects
  • Expertise includes model-informed drug development, model-informed precision dosing, and pharmacometrics in therapeutic areas such as oncology, immuno-oncology, and virology
  • Previously worked as Senior Scientist at Freie Universitaet Berlin, Germany, where she performed pharmacometric research in therapeutic areas such as oncology and immuno-oncology
  • Pharmacist (2017) and Dr.rer.nat. in Pharmacometrics (2021) from Freie Universitaet Berlin, Germany, and MBA (2025) from Trinity College Dublin, Ireland
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Model-based Analysis with Mechanistic Insights to CAR-T Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene AutoleucelDirect and hybrid machine learning approaches do not outperform NLME-based full Bayesian forecasting for early identification of delayed methotrexate eliminationA mechanism-based parsimonious CAR-T cell population PK model and its validation via extension to a population PK-tumor size dynamics model: case study with axicabtagene ciloleucel and brexucabtagene autoleucelPopulation Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Patients With Advanced Solid TumorsDevelopment of efficient CAR-T cell clinical study designs: Towards understanding of novel anticancer therapies through optimal experimental designA Bayesian-NLME approach identifies patients at risk of delayed MTX elimination if informative TDM data is providedA mathematical viral load model characterises the exposure- response relationship between bulevirtide and hepatitis delta virus and identifies the minimum duration of on-treatment viral load monitoring required for accurate prediction of long-term virologic responsePaediatric pharmacokinetic-pharmacodynamic extrapolation to identify suitable bulevirtide doses for children and adolescents with chronic hepatitis deltaExposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancerModel-informed early clinical development of BI-1808, a novel monoclonal antibody to tumor necrosis factor receptor 2Population pharmacokinetic analysis of Datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugate